SCCM is updating its SCCM Connect Community. Access to SCCM Connect may be limited until April 23.

Discovery VIRUS COVID-19 Registry

A global COVID-19 registry that tracks ICU and hospital care patterns in near real-time

visual bubble
visual bubble
visual bubble
visual bubble

Viral Infection and Respiratory Illness Universal Study (VIRUS) is a prospective, cross-sectional, observational study and registry of all eligible adult and pediatric patients who are admitted to a hospital. There is no intervention or patient interaction. Only de-identified data is used for analysis.  

ClinicalTrials.gov Identifier: NCT04323787

VIRUS COVID-19 Registry Dashboard

 

SCCM

 

Join the SCCM Connect Discovery Group

Approved sites with IRB approval can join the SCCM Connect Discovery Group. Access includes a discussion board and the ability to connect with other Discovery participants. This is best way to get regular updates about VIRUS.
 

Request to Join the Discovery SCCM Connect Group

VIRUS COVID-19 Registry Enrollment


Please check whether your site is already enrolled as a VIRUS participating site before enrolling.

Check the VIRUS Participation List
Complete the Intake Form to Participate 
VIRUS FAQs
 

Inclusion Criteria

  • COVID-19 PCR (or other SARS-CoV-2) test positive (within 21 days)
  • COVID-19 PCR pending
  • COVID-19 high clinical suspicion

Primary Aims

  • Create a real-time COVID-19 registry of current intensive care unit and hospital care patterns to allow evaluation of safety and observational effectiveness of COVID-19 practices 
  • Determine practice variations across hospitals

Hypothesis

The registry will be essential for near-real-time observational comparative effectiveness studies to determine effective treatment strategies and/or provide meaningful hypotheses for clinical trials. 


Institutional Review Board: Waiver of Consent

A waiver of informed consent for data collection is being requested for this study from participating sites. No patients will be contacted, but clinicians participating in the study will be surveyed for feedback and satisfaction. For any questions, contact Vishakha Kumar.

 

STOP-VIRUS ICU Learning Collaborative

Adult ICUs participating in the VIRUS Registry with at least 3-6 months of data and are located within the United States or its Territories, are invited to apply for a new SCCM collaborative being launched in February 2021. The collaborative, which will be open to twenty sites, is entitled STOP-VIRUS (Structured Team-based Optimal Patient-centered care for virus covid-19). There is no fee to participate. Applications are being accepted through mid-April.

visual bubble
visual bubble
visual bubble
visual bubble
visual bubble

VIRUS Investigators 

Discovery, the Critical Care Research Network, is leading the efforts for this global COVID-19 registry. 
Rahul Kashyap, MBBS, MBA
VIRUS Principal Investigator
Rahul Kashyap, MBBS, MBA


Co-Principal Investigators
Allan J. Walkey, MD, MSc, Boston University 
Juan Pablo Domecq Garces, MD, Mayo Clinic Foundation 
Vishakha Kumar, MD, MBA, Discovery Network, Society of Critical Care Medicine 

VIRUS Ancillary Studies

Ancillary study proposals may be submitted for a subset of de-identified data for research purposes by investigators of participating sites in the VIRUS study. 

The proposal submission period is now closed.
 

Information for Investigators

  • Any conflict of interest with the ancillary study proposal will be disclosed by the reviewers and the investigators.
  • The ancillary study proposals have been kept blinded from the VIRUS core investigator group. The first batch of ancillary proposals will be published once the review period closes and notifications are sent to the investigators.
  • SCCM, including the VIRUS core investigators group, has the first right upon publication of the dataset for research hypothesis outlined for the VIRUS Study.
  • Study participants can serve on the writing group with the VIRUS core investigators team, if their ancillary study ideas overlap or align with the VIRUS overall project aims.
  • Collaboration (national & international) on ancillary proposal submissions are encouraged.
  • Ancillary proposal approval and data sharing will also depend of data quality and completion of investigator’s own site data for the VIRUS study.

Ancillary Study Approval Process

Manuscript Approval Process